HNN3.0
Register
Register
Register

KelAda Pharmachem

Company (SME)

www.keladapharmachem.com/Dublin, Ireland
5 profile visits

About

OUR GOAL for the Cluster 1 Brokerage Event 2026 info day is to build relationships with ambitious partners for mutually beneficial collaborative opportunities.

KelAda Pharmachem Ltd is a research-intensive Irish SME, which leverages its synthetic chemistry and process development expertise (in particular using "Green Chemistry" technologies and processes) to develop compounds in high-value application areas (e.g. pharmaceuticals, nutraceuticals, fine chemicals etc).

KelAda’s mission is to catalyse the integration of “Green Chemistry” technologies into the manufacture of pharmaceutical ingredients and other high-value fine chemicals.

KelAda is experienced as both a partner in and coordinator of large-scale collaborative European projects. KelAda would be a strong partner for consortia within Horizon Europe Cluster 1 (Health) seeking a research-driven SME with expertise in synthetic chemistry and process development to design, develop, and validate custom active ingredients and advanced intermediates tailored to the specific needs of the consortium, from early-stage synthesis through scalable, application-ready solutions.

Contact us now to set up a meeting and explore collaborative opportunities with us!

Representatives

Research Programme Manager

KelAda Pharmachem

Marketplace (1)

  • Project cooperation

    Expertise offer: synthetic chemistry and process development

    KelAda is an Irish SME pioneering innovative, scalable chemistry solutions to develop high-value solutions that advance human health.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
    Author

    Research Programme Manager at KelAda Pharmachem

    DUBLIN, Ireland